🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Essen
Clinical trial register · Germany

Clinical Trials in Essen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca57 Novartis Pharmaceuticals50 Eli Lilly and Company30 Amgen27 University Hospital, Essen27
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Essen

760 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Active, closed
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
NCT06617793Relapsing Multiple Sclerosis
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 1/2
28
Bochum, Essen, Mainz, Ulm
2025-02-24
Recruiting
Efficacy of Add-on Plasma Exchange As an Adjunctive Strategy Against Septic Shock
NCT05726825Septic Shock
Hannover Medical School
Not applicable
274
Berlin, Bonn, Braunschweig, Bremerhaven, Cologne, Erlangen, Essen, Halle
2025-02-19
Active, closed
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236Platinum-resistant Ovarian Cancer
DrugsRina-S·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
Genmab
Phase 3
530
Berlin, Bonn, Dresden, Düsseldorf, Essen, Frankfurt, Giessen, Hamburg
2025-02-07
Recruiting
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
NCT06624670Pyoderma Gangrenosum
DrugsSpesolimab·Prednisolone·Prednisone
LEO Pharma
Phase 3
90
Berlin, Düsseldorf, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Tübingen, Würzburg
2025-02-05
Recruiting
Quality of Life and the Influence of Stress on the Postoperative Course of Patients After Device Implantation
NCT07343466Quality of Life (QOL) and Impact of Stress
University Hospital, Essen
Observational
300
Essen
2025-02-04
Active, closed
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
NCT06812325Thyroid Eye Disease (TED)
DrugVRDN-003
Viridian Therapeutics, Inc.
Phase 3
320
Berlin, Essen, Göttingen, Mainz
2025-02-03
Recruiting
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563Glioblastoma
DrugsTemozolomide·Keytruda·Pembrolizumab
NovoCure GmbH
Phase 3
741
Berlin, Essen, Frankfurt
2025-02-03
Recruiting
Cyclosporine In Takotsubo Syndrome
NCT05946772Takotsubo Cardiomyopathy
DrugCyclosporine A
University Hospital Heidelberg
Phase 2
204
Bad Nauheim, Berlin, Bonn, Cologne, Dresden, Düsseldorf, Essen, Frankfurt
2025-02-01
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Aachen, Berlin, Braunschweig, Chemnitz, Dresden, Düsseldorf, Essen, Göttingen
2025-01-28
Recruiting
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774Chronic Graft-versus-host-disease
DrugsAxatilimab·Prednisolone·Methylprednisolone·Prednisone
Incyte Corporation
Phase 3
240
Aachen, Berlin, Bonn, Dresden, Düsseldorf, Erlangen, Essen, Halle
2025-01-21
Recruiting
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
NCT06555419Muscular Atrophy, Spinal
DrugNusinersen
Biogen
Phase 1
78
Essen
2025-01-16
Recruiting
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126Melanoma, Cutaneous Malignant
DrugsAnzu-cel·Lifileucel·Temodar·Dacarbazine
Immatics US, Inc.
Phase 3
360
Cologne, Berlin, Bonn, Dresden, Erlangen, Essen, Frankfurt am Main, Hamburg
2025-01-14
Recruiting
Hemodynamic Effects of Anesthesia Induction
NCT06421181Patients Undergoing Anaesthesia Induction
Kliniken Essen-Mitte
Observational
30
Essen
2025-01-14
Active, closed
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)
DrugOcrelizumab
Amgen
Phase 3
152
Bad Homburg, Böblingen, Dresden, Ebersberg, Essen, Hamburg, Heidelberg, Leipzig
2025-01-13
Recruiting
Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status
NCT07803848Small-cell Lung Cancer
DrugTarlatamab
AIO-Studien-gGmbH
Phase 2
57
Berlin, Dresden, Essen, Flensburg, Frankfurt, Minden, München, Stuttgart
2025-01-01
Recruiting
Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
NCT06456359Desmoplastic Small Round Cell Tumor, Synovial Sarcoma
University Hospital Heidelberg
Phase 2
28
Heidelberg, Stuttgart, Essen
2024-12-19
Active, closed
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
NCT06742190Multifocal Motor Neuropathy (MMN), MMN
DrugsEmpasiprubart·Immunoglobulin·IVIG
argenx
Phase 3
154
Essen, Göttingen, Lübeck, Münster, Potsdam, Würzburg
2024-12-18
Recruiting
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
NCT06312644Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS)
DrugUltomiris
Alexion Pharmaceuticals, Inc.
Observational
75
Essen
2024-12-16
Active, closed
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
NCT06675864Progressive Multiple Sclerosis
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 1/2
28
Essen, Mainz, Ulm
2024-12-12
Active, closed
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
NCT06784648Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent
DrugsIpilimumab·Keytruda·Pembrolizumab
BioInvent International AB
Phase 1/2
35
Berlin, Essen, Heidelberg, Mannheim
2024-12-11
Active, closed
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide
Amgen
Phase 3
707
Berlin, Dresden, Düsseldorf, Essen, Hamburg, Heidelberg, Jena, Lübeck
2024-12-09
Active, closed
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
NCT06588686Idiopathic Pulmonary Fibrosis (IPF)
Vicore Pharma AB
Phase 2
378
Freiburg im Breisgau, Heidelberg, Tübingen, Frankfurt am Main, Immenhausen, Hanover, Essen, Berlin
2024-12-09
Recruiting
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation
DrugsElacestrant·Everolimus
MedSIR
Phase 3
300
Aschaffenburg, Augsburg, Dessau, Düsseldorf, Essen, Georgsmarienhütte, Worms
2024-12-05
Recruiting
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
NCT06607757CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
DrugsCapivasertib·Fulvestrant
GBG Forschungs GmbH
Phase 2
120
Augsburg, Berlin, Bielefeld, Bremen, Cologne, Cottbus, Dortmund, Essen
2024-12-04
Recruiting
Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study
NCT06689956FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage IA1 Endometrial Cancer FIGO 2023, Stage IA2 Endometrial Cancer FIGO 2023
Mayo Clinic
Observational
212
Essen
2024-12-04
Recruiting
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245Patients With Non-Small Cell Lung Cancer
DrugsTedopi·Docetaxel
OSE Immunotherapeutics
Phase 3
363
Heidelberg, Stuttgart, Gauting, München, Kassel, Aachen, Bonn, Essen
2024-12-03
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Berlin, Chemnitz, Essen, Jena, Würzburg
2024-11-27
Recruiting
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
NCT06613100Prostate Cancer
DrugXaluritamig
Amgen
Phase 1
40
Essen, Hamburg
2024-11-25
Active, closed
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older
NCT06460506Cystic Fibrosis
DrugELX/TEZ/IVA
Vertex Pharmaceuticals Incorporated
Phase 3
50
Berlin, Essen, Hanover
2024-11-21
Active, closed
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247Leukemia
DrugQuizartinib
Daiichi Sankyo
Phase 3
700
Alzenau in Unterfranken, Berlin, Braunschweig, Dresden, Essen, Hanover, Heidelberg, Kiel
2024-11-19
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel
AstraZeneca
Phase 3
1,160
Bad Berka, Berlin, Bielefeld, Bochum, Chemnitz, Cologne, Essen, Esslingen am Neckar
2024-11-18
Active, closed
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
DrugTaladegib
Endeavor Biomedicines, Inc.
Phase 2
213
Giessen, Immenhausen, Hanover, Essen, Berlin, Leipzig
2024-11-15
Recruiting
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
NCT06531499Metastatic Castration-Resistant Prostate Cancer
DrugLu-PSMA
Novartis Pharmaceuticals
Phase 1
106
Cologne, Wuppertal, Aachen, Berlin, Essen, München, Rostock
2024-11-11
Recruiting
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
NCT06380686Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Hypopharynx, Squamous Cell Carcinoma of the Larynx
AIO-Studien-gGmbH
Observational
120
Essen, Hanover
2024-11-07
Recruiting
Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)
NCT06784791Lung Cancer (NSCLC)
DrugsCarboplatin/pemetrexed·Amivantamab
University Hospital, Essen
Phase 2
20
Heidelberg, Essen
2024-11-06
Active, closed
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383Obesity
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
800
Villingen-Schwenningen, Lingen, Cologne, Essen, Leipzig, Oldenburg in Holstein, Hamburg
2024-11-01
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499Primary Immune Thrombocytopenia (ITP)
DrugEfgartigimod
argenx
Phase 3
69
Dresden, Essen
2024-10-18
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Erbitux·Amivantamab·Irinotecan
Janssen Research & Development, LLC
Phase 3
1,000
Berlin, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg, Mainz
2024-10-18
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Cologne, Essen, München, Rostock
2024-10-15
Active, closed
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
NCT06504394Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory
Drugs) Berahyaluronidase alfa·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
66
Essen
2024-10-14
Active, closed
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
NCT06625060Episodic Migraine, Chronic Migraine
DrugCorabotase
Ipsen
Phase 2
670
Berlin, Dresden, Essen, Frankfurt, Gera, Göppingen, Greifswald, Ulm
2024-10-10
Active, closed
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
NCT06630286HIV-1-infection
DrugsISL/LEN·B/F/TAF
Gilead Sciences
Phase 3
609
Berlin, Bonn, Cologne, Essen, Hamburg
2024-10-09
Recruiting
Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study
NCT06607302Cholangiocarcinoma
iOMEDICO AG
Observational
100
Augsburg, Bad Liebenwerda, Bad Mergentheim, Berlin, Dresden, Essen, Hanover, Hof
2024-10-08
Recruiting
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
NCT06602479Migraine
AbbVie
Phase 2
488
Berlin, Chemnitz, Dresden, Essen, Frankfurt am Main, Westerstede
2024-10-07
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
DrugsTagrisso·Datopotamab deruxtecan·Osimertinib·Pemetrexed
AstraZeneca
Phase 3
744
Berlin, Berlin-Zehlendorf, Bonn, Essen, Georgsmarienhütte, Giessen, Großhansdorf, Hamburg
2024-10-04
Recruiting
Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU)
NCT06569602Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases
Edwards Lifesciences
Observational
500
Bad Berka, Bad Nauheim, Bad Neustadt an der Saale, Bad Oeynhausen, Berlin, Bonn, Dortmund, Essen
2024-10-01
Active, closed
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Adagrasib·Sotorasib
Hoffmann-La Roche
Phase 3
338
Berlin, Cologne, Essen, Esslingen am Neckar, Gauting, Großhansdorf, Heidelberg, Hemer
2024-09-23
Recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin
Eli Lilly and Company
Phase 1
340
Berlin, Essen, Frankfurt am Main
2024-09-19
Active, closed
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
NCT06333951Thoracic Tumors, Non-small Cell Lung Cancer
DrugsAnvumetostat·Sotorasib·Pemetrexed·Paclitaxel
Amgen
Phase 1
49
Essen, Heidelberg, Würzburg
2024-09-17
Active, closed
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
NCT06430866Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
DrugsABP 234·Pembrolizumab
Amgen
Phase 3
163
Aschaffenburg, Essen
2024-09-12
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Irinotecan·Adrucil·Cetuximab
Eli Lilly and Company
Phase 1
630
Berlin, Dresden, Essen, München
2024-09-12
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384Lung Diseases, Interstitial
DrugBelimumab
GlaxoSmithKline
Phase 3
440
Essen, Minden, Mainz, Würzburg
2024-09-11
Active, closed
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
NCT06311721Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
DrugsABP 234·Keytruda·Pembrolizumab
Amgen
Phase 3
315
Essen, Hösbach, Landshut, Neumünster
2024-09-09
Active, closed
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
179
Stuttgart, Frankfurt am Main, Cologne, Leipzig, Jena, Essen, Lübeck, Mainz
2024-09-04
Recruiting
Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma
NCT06175845Cholangiocarcinoma, Klatskin Tumor, Bile Duct Cancer, Liver Cancer
Universitätsklinikum Hamburg-Eppendorf
Not applicable
130
Berlin, Bonn, Chemnitz, Essen, Hamburg, Hanover, Heidelberg, Lübeck
2024-08-30
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation
DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin
Bayer
Phase 3
555
Stuttgart, Nuremberg, Frankfurt am Main, Giessen, Cologne, Essen, Hemer, Berlin
2024-08-28
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441Endometrial Cancer
DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin
Gilead Sciences
Phase 3
640
Bad Homburg, Düsseldorf, Essen, Hamburg, Hanover, Leipzig, München, Ulm
2024-08-28
Active, closed
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498Multiple Myeloma
DrugsAnitocabtagene Autoleucel·Carfilzomib·Pomalidomide·Bortezomib
Kite, A Gilead Company
Phase 3
452
Berlin, Cologne, Essen, Freiburg im Breisgau, Hamburg, Leipzig, München, Tübingen
2024-08-23
Recruiting
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
NCT05583071Non-Hodgkin Lymphoma
DrugsTafasitamab·Methotrexate·Lenalidomide·Rituximab
University of Cologne
Phase 2
20
Stuttgart, Freiburg im Breisgau, Cologne, Hamburg, Essen, Berlin
2024-08-23
Recruiting
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy
DrugsRiliprubart·IVIG
Sanofi
Phase 3
160
Berlin, Bochum, Bremen, Essen, Göttingen, Hanover, Homburg, Münster
2024-08-21
Recruiting
One-Month DAPT in CABG Patients
NCT05997693Chronic Coronary Disease
DrugsTicagrelor·Aspirin
Weill Medical College of Cornell University
Phase 3
700
Düsseldorf, Essen, Freiburg im Breisgau, Giessen, Jena, München, Stuttgart
2024-08-15
Active, closed
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
NCT06313593Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
37
Aachen, Essen, Halle
2024-08-08
Active, closed
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
NCT06492291Hypercholesterolemia
DrugsEnlicitide·Enlicitide Decanoate
Merck Sharp & Dohme LLC
Phase 3
3,000
Essen, Dresden, Hohenmölsen, Bad Berka, Berlin
2024-08-05
Active, closed
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
NCT06440967Hot Flashes
DrugsFezolinetant·Tamoxifen
Astellas Pharma Global Development, Inc.
Phase 3
982
Essen, Bottrop, Dresden, Leipzig, Mönchengladbach, München, Münster, Wolfsburg
2024-07-31
Active, closed
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758Generalized Myasthenia Gravis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
146
Munich, Regensburg, Würzburg, Frankfurt am Main, Bochum, Essen
2024-07-31
Active, closed
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180Cervical Cancer
DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
686
Heidelberg, Heilbronn, Schwäbisch Hall, Munich, Marburg, Düsseldorf, Essen, Worms
2024-07-24
Active, closed
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
NCT06172127HER2-positive Breast Cancer
DrugsPhesgo·Trastuzumab deruxtecan
MedSIR
Phase 2
165
Bottrop, Essen, Hamburg, München
2024-07-22
Active, closed
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
976
Aachen, Bad Bentheim, Berlin, Bonn, Dresden, Düsseldorf, Essen, Hamburg
2024-07-19
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649Metastatic Colorectal Cancer
DrugsBevacizumab-awwb·Lumakras·Mvasi·Sotorasib
Amgen
Phase 3
450
Berlin, Chemnitz, Dresden, Essen, Frankfurt am Main, Hamburg, Ludwigsburg, München
2024-07-17
Active, closed
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
NCT06456346Essential Thrombocythemia
DrugsBomedemstat·Hydroxyurea
Merck Sharp & Dohme LLC
Phase 3
300
Landshut, Hanover, Aachen, Essen, Mainz, Halle, Jena, Berlin
2024-07-16
Recruiting
TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic Ataxias
NCT07798674Hereditary Spastic Paraplegia, Spastic Ataxia
Heidelberg University
Observational
4,000
Bochum, Bonn, Dresden, Erlangen, Essen, Göttingen, Heidelberg, Kiel
2024-07-16
Active, closed
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
NCT06161441Resectable Non-small Cell Lung Cancer
DrugsFianlimab·Paraplatin·Cemiplimab·Taxol
Regeneron Pharmaceuticals
Phase 2
195
Immenhausen, Essen, Großhansdorf, Esslingen am Neckar, Giessen, Hamburg, Hemer, Neuss
2024-07-16
Active, closed
Chronic Limb-Threatening Ischemia Treated With Intravascular Lithotripsy Observational Study
NCT06149650Chronic Limb-Threatening Ischemia
Cardiovascular and Interventional Radiological Society of Europe
Observational
400
Cologne, Essen, Hanover, Heilbronn, Karlsruhe, Mülheim, Neumünster, Rendsburg
2024-07-15
Recruiting
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
NCT06284590Melanoma Stage III, Melanoma Stage IV
DrugsDaromun·L19IL2·Onfekafusp alfa·Keytruda
Philogen S.p.A.
Phase 2
162
Essen, Freiburg im Breisgau, Kiel, Tübingen
2024-07-12
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Bad Homburg, Berlin, Bochum, Essen, Giessen, Tübingen
2024-07-12
Recruiting
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT06264180Advanced Melanoma
DrugsVusolimogene Oderparepvec·Relatlimab·Opdivo·Keytruda
Replimune, Inc.
Phase 3
400
Berlin, Dresden, Erfurt, Essen, Hamburg, Heidelberg, Kiel, Mainz
2024-07-11
Active, closed
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
NCT06248619Thyroid Eye Disease
DrugTeprotumumab
Amgen
Phase 3
89
Essen
2024-07-05
Recruiting
PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
NCT06102057Stage III Non-small Cell Lung Cancer, Locally Advanced, Unresectable
TheraOp
Phase 2
110
Dresden, Essen, Freiburg im Breisgau, Göttingen, Homburg, Mönchengladbach, München, Oldenburg
2024-07-01
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737Cutaneous Lupus Erythematosus
AstraZeneca
Phase 3
339
Berlin, Bochum, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hanover, Kiel
2024-06-29
Recruiting
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
DrugsZongertinib·Zanidatamab·Trastuzumab emtansine·MFOLFOX6
Boehringer Ingelheim
Phase 1/2
768
Dresden, Erlangen, Essen, Hamburg, Mannheim, Ulm
2024-06-28
Recruiting
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
NCT06392386Generalized Myasthenia Gravis
DrugEfgartigimod PH20
argenx
Phase 2/3
12
Essen
2024-06-28
Active, closed
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
NCT06496178Head and Neck Squamous Cell Carcinoma
DrugPetosemtamab
Merus B.V.
Phase 3
621
Berlin, Dresden, Essen, Giessen, Greifswald, Hanover, Leipzig, München
2024-06-25
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
DrugsSacituzumab tirumotecan·Nab-paclitaxel·Keytruda·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
851
Dortmund, Essen, Lübeck, Gera, Berlin
2024-06-10
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
DrugsTarlatamab·Durvalumab
Amgen
Phase 3
563
Cologne, Dresden, Essen, Gauting, Großhansdorf, Heidelberg, Münster, Würzburg
2024-06-05
Recruiting
Next-Generation-Sequencing Approach to Neutropenic Sepsis
NCT05815628Febrile Neutropenia
Boris Böll
Observational
400
Cologne, Dessau, Essen, Frankfurt am Main, Leipzig, Magdeburg
2024-06-05
Recruiting
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT06112314Advanced Melanoma
DrugsBrenetafusp·Relatlimab·Opdivo·Nivolumab
Immunocore Ltd
Phase 3
680
Berlin, Bremen, Dortmund, Dresden, Erfurt, Erlangen, Essen, Frankfurt
2024-06-05
Recruiting
Spinocerebellar Ataxia Type 27B Natural History Study (SCA27B-NHS)
NCT06472557Spinocerebellar Ataxia Type 27B
University Hospital Tuebingen
Observational
300
Tübingen, Essen
2024-06-04
Recruiting
Optimization of Radiation Protection Through Genomic Analyses
NCT06253338DNA, Cancer, Radiation
University Hospital, Essen
Not applicable
30
Essen
2024-06-01
Recruiting
Ultra-high-caloric, Fatty Diet in ALS
NCT06280079Amyotrophic Lateral Sclerosis
University of Ulm
Not applicable
392
Aachen, Berlin, Bochum, Bonn, Dresden, Erlangen, Essen, Göttingen
2024-06-01
Active, closed
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
NCT06401044Thyroid Eye Disease
DrugAMG 732
Amgen
Phase 1/2
94
Essen, Frankfurt am Main, Freiburg im Breisgau, Leipzig
2024-05-30
Active, closed
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
DrugsAnvumetostat·Modified FOLFIRINOX·Cetuximab·Nab-paclitaxel
Amgen
Phase 1
120
Essen, Heidelberg, Würzburg
2024-05-29
Recruiting
A Study of Pitolisant in Patients With Prader-Willi Syndrome
NCT06366464Prader-Willi Syndrome
DrugPitolisant
Harmony Biosciences Management, Inc.
Phase 3
134
Essen
2024-05-28
Recruiting
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210Small Cell Lung Cancer
DrugsAmrubicin·Ifinatamab Deruxtecan·Lurbinectedin·Topotecan
Daiichi Sankyo
Phase 3
540
Berlin, Erfurt, Essen, Frankfurt, Frankfurt am Main, Gauting, Gera, Giessen
2024-05-21
Active, closed
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms
DrugsTucatinib·Disitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
54
Berlin, Essen, Heidelberg
2024-05-20
Active, closed
The OPBC-07/microNAC Study
NCT06529302Breast Cancer
University Hospital, Basel, Switzerland
Observational
2,000
Augsburg, Düsseldorf, Essen, Heidelberg, Lübeck
2024-05-15
Active, closed
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
NCT05739942Newly Diagnosed and Recurrent Glioblastoma
Drugs[177Lu]Lu-NeoB·[68Ga]Ga-NeoB
Novartis Pharmaceuticals
Phase 1
42
Essen, München
2024-05-15
Recruiting
Essen Amyloidosis Registry
NCT06887283Amyloidosis; Systemic, Amyloidosis Cardiac
University Hospital, Essen
Observational
400
Essen
2024-05-08
Active, closed
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
DrugNerandomilast
Boehringer Ingelheim
Phase 3
1,666
Ahrensburg, Bamberg, Berlin, Bonn, Coswig, Essen, Hamburg, Hanover
2024-05-06
Recruiting
A Post Market Surveillance Study of the Hemovent Extracorporeal Cardiopulmonary Support System:The MOBYBOX Trial
NCT04183660Cardiac Failure, Respiratory Failure, Cardio-Respiratory Failure, Imminent Cardiorespiratory or Respiratory Failure
Hemovent GmbH
Observational
60
Hanover, Essen, Halle, Erfurt
2024-04-30
Active, closed
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
DrugRetatrutide
Eli Lilly and Company
Phase 3
10,000
Bad Nauheim, Bad Oeynhausen, Berlin, Bremen, Dortmund, Dresden, Elsterwerda, Essen
2024-04-30
Rows per page Showing 201–300 of 760
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/essen?page=3

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 760 of those studies with a site in Essen.

How many clinical trials are recruiting in Essen?

375 of the 760 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 15 have not yet opened recruitment, 361 are active but closed to new participants, and 9 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.